Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...

Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).

An analysis of major depressive disorder, covering diagnostic criteria, prevalence statistics across demographics, and ...

Biohaven Ltd. recently reported that its Phase 2 proof-of-concept trial of BHV-7000 for major depressive disorder failed to meet the primary MADRS endpoint over six weeks versus placebo, although the ...

Adding a daily fish oil supplement to psychotherapy showed no significant benefit over placebo for kids and teens with ...

The major depressive disorder failure for BHV-7000 is the drug's second, after Biohaven’s spinocerebellar ataxia treatment ...

Depression, one of the most prevalent mental health disorders worldwide, is characterized by persistent feelings of sadness, ...

Overall tolerability and safety were observed, with adverse events primarily mild or moderate and resolving spontaneously.

Researchers compared a traditional Chinese medicine, Yueju Pill, with a standard antidepressant and found both reduced ...

Patients with first-episode MDD showed lower effective and functional connectivity between the anterior cingulate cortex and frontal regions.